Esta compañía no ha anunciado ningún dividendo en el próximo trimestre, ni ha pagado dividendos en el último año.
Sobre Immutep Ltd.
Marc Voigt, MBA
SydneyNew South Wales (NSW)
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.